Search

Subject Anti-TNF -- Rheumatoid Arthritis -- Treatment

1. A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. Issue 1 (14th January 2016)

Authors:
Chatzidionysiou, Katerina; Turesson, Carl; Teleman, Annika; Knight, Ann; Lindqvist, Elisabet; Larsson, Per; Cöster, Lars; Forslind, Kristina; van Vollenhoven, Ronald; Heimbürger, Mikael
Journal:
RMD open
Issue:
Volume 2:Issue 1(2016)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab. Issue 11 (5th June 2013)

Authors:
Plasencia, Ch; Pascual-Salcedo, D; Alcocer, P; Bonilla, M G; Villalba, A; Peiteado, D; Arribas, F; Díez, J; Lopez-Casla, M T; Martín-Mola, E; Balsa, A
Journal:
Annals of the rheumatic diseases
Issue:
Volume 72:Issue 11(2013)
Page Start:
1888
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search

  • Anti-TNF -- Rheumatoid Arthritis -- Treatment 2